East Brunswick, NJNCT07719361Now EnrollingIRB Ready

Metastatic Castration Resistant Prostate Cancer Clinical Trial in East Brunswick, NJ

Access cutting-edge metastatic castration resistant prostate cancer treatment through this phase 1 clinical trial at a research site in East Brunswick. Study-provided care at no cost to qualified participants.

Sponsored by Flare Therapeutics Inc.

Quick Self-Assessment

See if you qualify for this East Brunswick location

Preparing your pre-screening questions…

Expert Care in East Brunswick

Access metastatic castration resistant prostate cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related metastatic castration resistant prostate cancer treatment provided free

Apply for This East Brunswick Location

Check if you qualify for this metastatic castration resistant prostate cancer clinical trial in East Brunswick, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to East Brunswick

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit East Brunswick site if eligible
  4. 4Begin participation

About This Metastatic Castration Resistant Prostate Cancer Study in East Brunswick

The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRPC. The main questions it aims to answer are: What are the side effects of FX-111? Does FX-111 work to reduce or prevent progression of mCRPC? The study doctor will oversee participants' treatment with FX-111 and ask about any side effects. Participants will take FX-111 every day by mouth and will have regular physical and laboratory examinations to check health and tumor status.

Sponsor: Flare Therapeutics Inc.

Who Can Participate

Inclusion Criteria

Confirmed adenocarcinoma of the prostate.
PSA levels ≥ 2 ng/mL at screening visit.
Progressing PSA, defined as two consecutive increases in the most recent PSA measurements taken at least 1 week apart.
Progressed on Androgen Deprivation Therapy (ADT) and at least one prior potent Androgen Receptor (AR) pathway inhibitor given in castration-sensitive prostate cancer setting or approved for castration-resistant prostate cancer (eg, apalutamide, darolutamide, abiraterone, enzalutamide).
Ongoing primary ADT with gonadotropin-releasing hormone agonist or antagonist in the absence of bilateral orchiectomy.
Acceptable physical functioning and laboratory measurements, per the study protocol.
Discontinued prior therapies within protocol-specified timeframes.
Commit to use of highly-effective contraception while on study and for 90 days after.
Willing and able to adhere to the study visit schedule and other protocol defined requirements.

Exclusion Criteria

Predominance of small cell carcinoma of the prostate/neuroendocrine prostate cancer in most recent tumor biopsy.
Participants with brain metastases that require ongoing treatment with radiation or high-dose steroids.
Not recovered from side effects of prior surgery or cancer treatments.
Evidence of active viral, bacterial, or fungal infection requiring treatment with antivirals, antibiotics, or anti-fungal medications.
Prior treatment with AR degraders and molecules with an AR ligand such as AR Regulated Induced Proximity Targeting Chimera (RIPTAC).
Blood clots ≤ 4 weeks prior to start of treatment.
Concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study drug. Patients may be eligible if the malignancy is clinically stable or has been treated with curative intent.
Any evidence of severe or uncontrolled systemic diseases.
Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of the patient's safety or study results.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in East Brunswick?

Yes, this clinical trial (NCT07719361) has an active research site in East Brunswick, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Metastatic Castration Resistant Prostate Cancer Treatment Options in East Brunswick, NJ

If you're searching for metastatic castration resistant prostate cancer treatment options in East Brunswick, NJ, this clinical trial (NCT07719361) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our East Brunswick research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced metastatic castration resistant prostate cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all metastatic castration resistant prostate cancer clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in East Brunswick, NJ

See all prostate cancer clinical trials recruiting in East Brunswick — not just this study.

Browse Prostate Cancer Trials in East Brunswick →

Browse More Trials by Condition

Prostate Cancer TrialsEssential Tremor TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in East Brunswick?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · East Brunswick, NJ